ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
Identification of cystatin SN as a novel biomarker for pancreatic cancer.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 57 citations in OpenAlex.
- CST1 Regulates ER-Mitochondrial Mg²⁺ Balance via MAGT1 to Promote Breast Cancer Metabolism and Growth.International journal of biological sciences · 2026Article
- AmiCa: Atlas of miRNA-gene correlations in cancer.Computational and structural biotechnology journal · 2024Article
- Cystatin SN (CST1) Is a Poor Independent Prognostic Biomarker for Gastrointestinal Diffuse Large B-Cell Lymphoma.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Review
- MiR-942-5p inhibits tumor migration and invasion through targeting CST1 in esophageal squamous cell carcinoma.PloS one · 2023Article
- Article
- Transcriptional factor III A promotes colorectal cancer progression by upregulating cystatin A.World journal of gastrointestinal oncology · 2022Article
- Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma.BMC cancer · 2022Article
- Gender-related differentially expressed genes in pancreatic cancer: possible culprits or accomplices?Frontiers in genetics · 2022Article
- Cystatin C and cystatin SN as possible soluble tumor markers in malignant uveal melanoma.Radiology and oncology · 2021Article
- Prognostic marker identification based on weighted gene co-expression network analysis and associatedBioengineered · 2021Article
- Identification of crucial long non-coding RNAs and mRNAs along with related regulatory networks through microarray analysis in esophageal carcinoma.Functional & integrative genomics · 2021Article
- Mining the plasma-proteome associated genes in patients with gastro-esophageal cancers for biomarker discovery.Scientific reports · 2021Article
- miRNA-6715-5p Inhibits Cellular Proliferation and Invasion in Colorectal Cancer by Directly Targeting CST4.Journal of oncology · 2021Article
- CST1 Promoted Gastric Cancer Migration and Invasion Through Activating Wnt Pathway.Cancer management and research · 2021Article
- α-Enolase Lies Downstream of mTOR/HIF1α and Promotes Thyroid Carcinoma Progression by Regulating CST1.Frontiers in cell and developmental biology · 2021Article
- Identification of Cysteine Protease Inhibitor CST2 as a Potential Biomarker for Colorectal Cancer.Journal of Cancer · 2021Article
- Development and Evaluation of Serum CST1 Detection for Early Diagnosis of Esophageal Squamous Cell Carcinoma.Cancer management and research · 2021Article
- RP-HPLC-ESI-IT Mass Spectrometry Reveals Significant Variations of the Human Salivary Protein Profile Associated with Predominantly Antibody Deficiencies.Journal of clinical immunology · 2020Article
- Upregulation of cystatin SN promotes hepatocellular carcinoma progression and predicts a poor prognosis.Journal of cellular physiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystatin SN (cystatin 1, CST1) is a member of the cystatin superfamily that inhibits the proteolytic activity of cysteine proteases. CST1 is a tumor biomarker that provides useful information for the diagnosis of esophageal, gastric, and colorectal carcinomas. However, the significance of CST1 in pancreatic cancer is unknown. The aim of this study was to assess whether CST1 is a potential biomarker for early diagnosis of malignant pancreatic neoplasms. Microarray analysis of mRNA extracted from pancreatic cancer and pancreatic normal tissues was performed. Bioinformatics revealed that CST1 was one of the highest expressed genes on the array in pancreatic cancer, compared with normal tissue. In addition, the upregulation of CST1 in pancreatic cancer and several pancreatic cancer cell lines was confirmed using real-time PCR (RT-PCR), immunohistochemistry, and Western blotting. Next, CST1 knockdown using siRNA reduced the expression of the proliferation-related proteins p-AKT and PCNA significantly, as well as colony formation and xenograft development in vitro. Consistent with this, CST1 mRNA overexpression was correlated closely with malignancy-associated proteins such as PCNA, cyclin D1, cyclin A2, and cyclin E in pancreatic cancer cell lines. In conclusion, our data suggest that CST1 might contribute to the proliferation of pancreatic cancer cells and could be a potential biomarker for the early detection of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.